The letter by Alderman and colleagues is a timely reminder of the continued importance of post-marketing surveillance, especially for medications with frequently encountered and well characterised harms. As outlined, such surveillance must include all medications, whether or not they are subsidised or sold over the counter, in order to account for drug–host and drug–drug interactions.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
- 1. Takai Y, Yamamoto-Mitani N, Okamoto Y, et al. Literature review of pain prevalence among older residents of nursing homes. Pain Manag Nurs 2010; 11: 209-223.
- 2. Baier RR, Gifford DR, Patry G, et al. Ameliorating pain in nursing homes: a collaborative quality-improvement project. J Am Geriatr Soc 2004; 52: 1988-1995.
- 3. Currow DC, Rowett D, Doogue M, et al. An international initiative to create a collaborative for pharmacovigilance in hospice and palliative care clinical practice. J Palliat Med 2012; 15: 282-286.
- 4. Zulman DM, Sussman JB, Chen X, et al. Examining the evidence: a systematic review of the inclusion and analysis of older adults in randomized controlled trials. J Gen Intern Med 2011; 26: 783-790.
- 5. NPS MedicineWise [website]. Best practice opioid analgesic prescribing for chronic pain. Sydney: NPS MedicineWise, 2015. http://www.nps.org.au/conditions/nervous-system-problems/pain/for-individuals/pain-conditions/chronic-pain/for-health-professionals/opioid-medicines/best-practice-prescribing (accessed June 2016).
Online responses are no longer available. Please refer to our instructions for authors page for more information.
No relevant disclosures.